Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03257969

Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors

The rise of oral anticancer drugs favors outpatient care but exposes patients to new risks compared to injectable chemotherapy at hospital: non-adherence to treatment, inappropriate management of side effects and interactions with other co-prescribed drugs. Latrogenic risk of these treatments is reinforced in older patients with frequent comorbidities, taking multiple pharmaceutical treatments for long periods and followed by several prescribers.

The literature reports an emergence of drug related problems (DRP) in more than 90% of patients, with an average number of 0 to 4 per patient. The clinical consequences (reduced efficacy and potentiation of toxicity) are all the more important that outpatient monitoring of treatments prescribed at the hospital remains underdeveloped due to default of coordination between these two settings.

Medical care and prevention of these DRP are difficult because of a lack of information and tools shared between hospital and liberal actors. Experiments are developed according to different organizational models, frequently focused on the pharmaceutical analysis of prescriptions, the detection of DRP and their control, but they stay still undervalued. In this context, the French Society of Oncological Pharmacology (SFPO - Société Française de Pharmacie Oncologique) provides to hospital and ambulatory care pharmacists the Oncolien website and proposes to assess the impact of a program of pharmaceutical interventions named DROP. The hypothesis of the study is that the DROP program will secure the medical care of patients with oral anticancer drugs compared to the usual care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 18 years old or more
  • With cancer
  • For wich the initiation or change of an oral anticancer drug is prescribed
  • With life expectancy estimated to be 6 months or more, in the opinion of the investigator
  • Of which the treatment with oral anticancer medication is estimated to be 6 months or more in the opinion of the oncologist
  • Benefiting from an initiation or a change of oral anticancer agents according to the MA: cytotoxic agent, targeted therapy, hormonal therapy (excluding adjuvant treatments);
  • of which the oral anticancer drug is delivered in pharmacy of town or in retrocession hospital;
  • With ambulatory status (not hospitalized for the management and treatment )
  • Taking 5 or more drugs, including the oral anticancer treatment, and / or treated with an oral anticancer drug requiring complex regimen (combination of 2 oral anticancer drugs, or sequential rate of intake, or associated to intravenous chemotherapy)
  • With a sufficient autonomy for the management of medication at home
  • Without either cognitive disorders or major psychiatric disorders, in the opinion of the investigator
  • Ability to read, write and understand the French language
  • Having given his written consent to participate in the study
  • Patient affiliated to the social security scheme or equivalent

Exclusion criteria

  • Pregnant or lactating woman
  • Patient on anti-PD1, anti-PDL-1 or anti-CTLA4-4 immunotherapy concomitant with oral anticancer treatment
  • Patient under radiotherapy concomitant treatment with oral anticancer
  • Oral anticancer agent prescribed in a delivery circuit as part of an ATU or clinical trial;
  • Patient with significant cognitive or psychiatric disorders, in the opinion of the investigator;
  • Management of drug treatment at home is performed exclusively by the caregiver;
  • Not having declared a doctor;
  • Not having a usual city pharmacy, or reporting 2 or more usual city pharmacies;
  • Patient who has already benefited from a therapeutic education program
  • In institution or guardianship, major protected by the Law.

Treatment and study plan

The DROP program of pharmaceutical interventions

Behavioral

Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.

Standard of Care

Behavioral

In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.

Primary outcomes

  1. Number of DRP (Drug Relates Problems) related to oral anticancer drugs per patient, in total and for each category

    Time frame: 9 months post-inclusion

    DRP are defined as the number of: adverse reactions (grade 2-3-4); drug interactions (contraindication, association not recommended, precautionary use); and medication errors with proven harm or requiring appropriate monitoring (Medication Error Index of the National Coordinating Council for Medication Error Reporting and Prevention, grade D to I).

Secondary outcomes

  1. Total number of DRP related to all prescribed drugs per patient

    Time frame: 6 months and 9 months post-inclusion

    DRP are defined as the number of: adverse reactions (grade 2-3-4); drug interactions (contraindication, association not recommended, precautionary use); and medication errors with proven harm or requiring appropriate monitoring (Medication Error Index of the National Coordinating Council for Medication Error Reporting and Prevention, grade D to I).

  2. Number of adaptations in the prescription of oral anticancer drugs, related to DRP, per patient

    Time frame: 6 months and 9 months post-inclusion

    dose adjustments, cure spacing, interruptions and cessation of treatment.

  3. Relative dose intensity of the oral anticancer drug

    Time frame: 6 months post-inclusion

    Relative dose intensity will be computed by the ratio between the overall dose prescribed during the 6 months of follow-up and the theoretical dosage according to the summary of product characteristics of the market authorization.

  4. Adherence to the oral anticancer drug

    Time frame: 6 months post-inclusion

    Adherence will be measured with the Girerd questionnaire score 6 items from the Ameli Health Insurance website and the rate of prescription renewal by the ambulatory pharmacy (adherence will be defined as a rate ≥80%).

  5. Number of imaging acts and nature of acts

    Time frame: During the 6 months of follow-up

    To evaluate consumption of unscheduled ambulatory care related to DRP

  6. Number of acts of biology and nature of acts

    Time frame: During the 6 months of follow-up

    To evaluate consumption of unscheduled ambulatory care related to DRP

  7. Number of medical consultations

    Time frame: During the 6 months of follow-up

    To evaluate consumption of unscheduled ambulatory care related to DRP

  8. Number of prescriptions of drugs (without prescription of the oral anticancer drug) and nature of these drugs

    Time frame: During the 6 months of follow-up

    To evaluate consumption of unscheduled ambulatory care related to DRP

  9. Number of hospital admissions

    Time frame: During the 6 months of follow-up

    To evaluate unplanned hospital admissions related to DRP

  10. Patient's quality of life, measured with the EuroQol 5-Dimensions questionnaire

    Time frame: At inclusion and 6 months from the treatment initiation

  11. Patient's satisfaction with treatment, measured with the SAT-MED Q questionnaire

    Time frame: At inclusion and 6 months from the treatment initiation

  12. Health locus of control, measured with the Therapeutic Self Care Toll (TSCT) scale

    Time frame: At inclusion and 6 months from the treatment initiation

  13. Number of interventions of primary care actors with the patient

    Time frame: During the 9 months of follow-up

    To evaluate the involvement of primary care actors in the DROP program

  14. Number of time the Oncolien website was used by ambulatory care pharmacists

    Time frame: During the 9 months of follow-up

    To evaluate the involvement of primary care actors in the DROP program

  15. Number of forms helping the delivery of the oral anticancer drug used by ambulatory care pharmacists

    Time frame: During the 9 months of follow-up

    To evaluate the involvement of primary care actors in the DROP program

  16. Number of patient-advice forms downloaded and delivered to the patient

    Time frame: During the 9 months of follow-up

    To evaluate the involvement of primary care actors in the DROP program

  17. Number and reason for solicitations of hospital actors by the primary care actors, in the context of information sharing

    Time frame: During the 9 months of follow-up

    To evaluate the involvement of primary care actors in the DROP program

  18. Patient's satisfaction for the DROP program

    Time frame: At 9 months post-inclusion

    Satisfaction will be measured with a 10-point visual analog scale.

  19. Ambulatory care physician's and pharmacist's satisfactions with the DROP program

    Time frame: At 9 months post-inclusion

    Satisfaction will be measured with a 10-point visual analog scale.

  20. Efficiency of the DROP program

    Time frame: 9 months post-inclusion

    Efficiency will be computed by the incremental cost-efficacy ratio between the DROP program and the usual care.

Study contacts

Contact information is provided by the study sponsor or research team.

Catherine RIOUFOL, PharmD

CONTACT

[email protected]

04 78 86 43 70 ext. +33

Laure HUOT, PharmD

CONTACT

[email protected]

04 72 11 57 62 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Impact of the DROP (Drug Related Problems in Oncology Practice) Program of Pharmaceutical Interventions of the French Society of Oncological Pharmacology Versus Usual Care on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors

Acronym: DROP-SFPO

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Aug 22, 2017
Registry last updated
Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.